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ABSTRACT 
Since exogeneous catecholamines potentiate ADP-induced aggregation 
in vitro, and this effect is blocked directly by phentolamine, it 
was assumed that platelets from patients with pheochromocytoma 
would be unusually sensitive to ADP and that this sensitivity 
would be reduced in the presence of phentolamine. Findings in 
four patients with pheochromocytoma were compared to results in 
20 normals. Phentolamine had no immediate effect in either group. 
Pheochromocptoma platelets became more responsive to ADP after 
standing and this increase in responsiveness was inhibited by phen- 
tolamine. These results: 1) suggest that catecholamine concentra- 
tions in the plasma of patients with pheochromocytoma are not high 
enough to potentiate ADP aggregation and 2) may be explained by 
assuming that pheochromocytoma platelets are saturated with cat- 
ecbolamines. 
INTRODUCTION 
Catecholamines induce (1) and potentiate (2) blood platelet aggregation 
when studied "in vitro". Whether this phenomenon occurs "in viva" in humans 
is not known, although it has been suggested, particularly in discussions of 
factors precipitating acute myocardial infarction, and there is some indirect 
evidence to support this view (3). In considering strategies to get directly 
at this question, the study of patients with pheochromocytoma was selected as 
being a practical approach to obtain relevant information. Since catechola- 
mines in nearly physiologic concentrations potentiate ADP-induced platelet 
aggregation, and this effect is prevented by the alpha-adrenergic blocking 
agent, phentolamine (2,4), it was hypothesized that platelets from patients 
with pheochromocytoma would be unusually sensitive to ADP and that this sen- 
sitivity could be unmasked by phentolamine. We report here the results of 
such studies in four patients with pheochromocytoma as contrasted to findings 
in a control group. Also reported are the results of preliminary studies 
which were required for the development of an appropriate experimental design. 
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METHODS 
Subjects 
One patient with pheochromocytoma and twenty healthy adults provided 
blood for preliminary experiments and another twenty healthy adults were bled 
for the definitive experiment. Four patients with pheochromocytoma were the 
main subjects of investigation in the definitive experiment (Table 1). All 
subjects had taken no medication for at least seven days prior to venesection. 
TABLE 
1 
Clinical Data from Four Patients with Pheochromocytoma 
Catecholamines 
Blood Pressure pg/24O Urine Tumor Weight 
Patient Age Sex mm Eg Epinephrine Norepinephrine (Grams) 
T.K. 19 F 180/110 < 1.0 838 49 
R.T. 10 M 190/150 312 1430 16 
T.T. 9 M 160/115 163 2266 12 
R.A. 24 M 155/100 16 757 25 
Platelet Aggregation 
Studies were carried out on venous blood drawn into plastic or siliconized 
glass syringes containing 3.8% sodium citrate (9 parts blood to 1 part citrate). 
Tests were performed either at room temperature or at 3J°C utilizing previously 
described turbidimetric techniques (5,6). Phentolamine (RegitineR CIBA) was 
diluted with normal saline solution to provide the concentrations indicated in 
the various experiments. 
Preliminary Experiments 
1. Effect of phentolamine on platelet aggretation in one patient with 
pheochromocytoma. 
Responses to l.OM X 10s6 and 5.OM X 10s6 ADP were studied at room temper- 
ature. Aggregation was induced 1 minute after the addition of phentolamine 
10m4M and lo-6M to the platelet rich plasma (PRP). Maximum aggregation in the 
presence of phentolamine was contrasted to that observed in the presence of an 
equal volume of saline. Phentolamine lo-91 had no effect but 10w4M produced 
a striking reduction of the maximum rise (MR) of the aggregation curve. 
2. Effect of phentolamine on platelet aggregation in normal subjects. 
Aggregation with ADP lo-6M in the presence of saline or phentolamine was 
studied at room temperature. Response in the presence of phentolamine lO-6M 
was compared to saline controls. If no inhibition was apparent at 10'6M the 
procedure was repeate at 10w5M, and, if indicated, at 1O'4M. It was found 
that phentolamine lo- 4 consistently inhibited ADP aggregation, while lower 
concentrations did not. 
3. Phentolamine inhibition of adrenaline-potentiation of ADP aggregation: 
effect of prolonging PRP exposure to adrenaline. 
Aliquots of PRP were incubated in the presence of 1X 10w8M adrenaline 
(Parke-Davis) for specified times at room temperature. Saline was then added, 
and aggregation was induced with lo-6M ADP 1 minute later. This procedure 
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was repeated on a duplicate sample of PRP, but phentolamine 10-h was added in 
the place of saline prior to aggregation with ADP. Samples were incubated 
with adrenaline for 1, 3, 5, 15, and 35 minutes. Studies were performed at 
room temperature on PRP from three normal subjects. It was found that 
incubation with adrenaline for periods up to 35 minutes did not alter the 
potentiating effect of adrenaline on the ADP response or phentolamine's 
ability to block that potentiation (Fig. 1). 
PHENTOLAMINE INHIBITION OF ADRENALINE FOTENTIATION 
OF ADf AGGREGATION 
(EFFECT OF DURATlON OF ADRENALINE lNCUBATlON) 
ADP IO* M FHENTOLAMlNE lobfvl 
+ ADP lO%l 
SALINE 
ADRENALINE IO* M 





BP-induced aggregation in the presence of phentolamine after brief and pro- 
longed exposure to a potentiating concentration of adrenaline. Studies were 
performed on aliquots from one plasma sample. MR =i maximum rise. 
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Experimental Design 
Aggregation at Room Temperature 
Aggregation with ADP 10% in the presence of either saline 
or phentolamine 10T6M was compared. PRP was allowed to stand with saline 
for 1 minute before addition of ADP, and then another aliquot utilizing 
phentolamine in place of saline was studied. The same procedure was repeated 
with a pair of samples incubated at room temperature with saline and phen- 
tolamine respectively for a period of 30 minutes prior to aggregation. 
Aggregation at 37'C 
Studies were performed in the same manner as those at room temperature, 
except that: 1) the incubation period was extended to 80 minutes, 2) the 
ADP concentration was individualized for each subject so that the minimal 
concentration of ADP needed to induce a second wave of aggregation was util- 
ized (the "ADP endpoint" concentration). 
RESULTS 
Nregation at Room Temperature 
In control subjects aggregation was uninfluenced by phentolamine; even 
prolonged exposure-to it <Table 2). In patients immediate aggregation was 
not significantly different from control subjects. However, the ADP response 
of pheochromocytoma platelets was more intense after 30 minutes of standing 
(MR = 68.3 + 14.2 as compared to 39.5 + 1.8 without standing). This change 
on standing was not observed in control subjects and proved to be highly sig- 
nificant (p <O.OOl). Although aggregation was slightly less in patients after 
short exposure to phentolamine, this effect was not greater than that observed 
in control subjects under these conditions. However, aggregation of pheo- 
chromocytoma platelets was clearly inhibited by 30 minutes exposure to phen- 
tolamine. 
Aggretation at 37'C 
"ADP End-point" 
In coftgrol subjects end-point concentrations ranged from l.OM X loo6 to 
5.OM X 10 with a mean of 2.OM X 10W6. The mean value for patients with 
pheochromocytoma was also 2.OM X 10-6 with a range from 1.0 to 4.OM X 10-6. 
Effect of Phentolamine on ADP Aggregation 
Immediate aggregation in saline was similar in both groups of subjects 
and there was no evidence of a direct inhibitory effect of phentolamine 
(Table 2). Responses in the groups were clearly different after prolonged 
standing in the presence of the alpha blocker. Aggregation after 80 minutes 
of phentolamine was inhibited in patients, but not among controls (Fig. 2). 
This phenomenon was not observed in one patient (R.A.) studied eight months 
after removal of his tumor (Fig. 2). 
DISCUSSION - 
Adrenaline (and nor-adrenaline) can influence human blood platelet ag- 
gregation in three ways when studied in vitro. In concentrations greater 
than lo-6M adrenaline causes biphasic aggregation (2,7) but in the 10m7M 
range a uniphasic response is typically all that is seen (2,8). At lower 
concentrations, usually not less than 10'8M, the presence of adrenaline is 
manifested by an increased sensitivity to aggregation induced by ADP (2). 
Plasma concentrations of catecholamines in humans normally are in the 
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10pgM range (9). Higher concententrations are found in patients 




range. We therefore designed our platelet aggregation studies in such a way 
as to uncover heightened sensitivity to ADP in patients with this disorder. 
80 minutes I minute 
80 minutes I minute 





ADP-induced aggregation in the presence of phentolamine in a normal subject 
and a patient with pheochromocytoma. 
Prel'minary investigation in one patient with pheochromocytoma revealed 
that lo- &l 
10% did. 
phentolamine did not have an immediate inhibitory effect, whereas 
A subsequent experiment to find the optimal concentration of 
phentolamine to utilize in further studies of patients revealed that lo-4M 
was inhibitory to all platelets whereas lo-6M was not. A non-specific in- 
hibitory effect of high concentrations of phentolamine has in fact been sug- 
gested by others (11,12). The concern that prolonged exposure of platelets 
to adrenaline might interfere with phentolamine's ability to block its poten- 
tiating effect on ADP aggregation led to a final preliminary experiment which 
demonstrated that this was not the case. Nevertheless, in view of the obser- 
vation that 10% phentolamine had not had an immediate effect in our first 
patient, the definitive experiment was designed so as to study the effects of 
both immediate and prolonged *osure to phentolamine. 
Analysis of the data collected in this study resulted in three major 
findings. First, pheochromocytoma platelets are no more aggregable in re- 
sponse to ADP than normal ones. This finding tends to deny the hypothesis 
that catecholaminezpotedtiated ADP aggregation occurs in patients with this 
clinical problem. However, in view of the considerable variability of ADP 
response, and the small number of patients included in this study, no firm 






















































































































































































































































































































































































































report in the clinical literature which bears on the present investigation 
is in fact not in agreement with these results. Danta (13) has reported 
that platelet adhesiveness declines in patients with pheochromocytoma after 
tumor removal, suggesting the presence of heightened platelet responsiveness 
preoperatively. 
The second noteworthy finding in this study is related to a pair of 
observations: the lack of inhibition of ADP aggregation of pheochromocytoma 
platelets by a 1 minute exposure to phentolamine lo-91 and the absence of 
a difference in ADP end-points between patients and controls. Both of these 
observations support the impression, already suggested, that there is not 
catecholamine potentiation of the ADP response in patients with pheochromo- 
cytoma. 
The third interesting finding in the study is the demonstration that 
prolonged exposure to phentolamine is inhibitory to pheochromocytoma platelets. 
This might be explained by assuming that prolonged contact is needed for 
phentolamine to compete effectively with catecholamines that have had ample 
opportunity to saturate the alpha receptor sites. Another hypothesis is 
suggested, however, by the fact that ADP responses increase substantially 
after platelets from patients stand at room temperature for as little as 
30 minutes. It is well known that the reactivity of normal platelets varies 
considerably during standing. Most observers have found a slight increase 
of either platelet adhesiveness or ADP response after 1 or 2 hours and then 
a gradual decline (14,15). Recently a time-dependent increase in responsive- 
ness after incubation at 37°C to epinephrine and collagen also has been re- 
ported (16). The increment in ADP response has been attributed to alteration 
of platelet membrane permeability with associated leakage of ADP into the 
plasma (17). 
Normal human platelets contain very small quantities of catecholamines, 
but there is indirect evidence to suggest that these may be of some impor- 
tance in platelet aggregation (18). Also, there are data which indicate 
that there is a slow spontaneous release of catecholamines from platelets 
resuspended in artificial medium (19). It is conceivable that pheochromo- 
cytoma platelets contain more catecholamines than normal ones, since platelets 
have been found to actively absorb both adrenaline (12,19) and nor-adrenaline 
(20) in vitro. If it is assumed that pheochromocytoma platelets are rich in 
catecholamines and that these leak out in substantial quantity during standing, 
then it can be seen how a potentiated ADP response might result and that this 
would be inhibited by phentolamine. The difference in results of aggregometry 
performed at room temperature and 37°C may be explained by a combination of 
metabolic inactivation and reuptake of released epinephrine during incubation 
at 37'C prior to addition of ADP. 
It appears then, that pheochromocytoma platelets behave differently than 
normal platelets, but not in the manner which one might have predicted. They 
do not behave as if they were surrounded by catecholamines in concentrations 
high enough to potentiate ADP aggregation, but they tend to become more re- 
active during standing. The results may be interpreted to suggest that these 
platelets contain large amounts of catecholamines. This hypothesis deserves 
direct testing, since, if correct, it could lead to the development of simpli- 
fied blood tests for the detection of pheochromocytoma rather than present 
methods which require urine collection over a period of time. 
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